Metastatic castration resistant prostate cancer patients’ experience with Radium-223 treatment in Japan

<b>Aim:</b> We aimed to determine Japanese metastatic castration resistant prostate cancer (CRPC) patients’ Ra-223 treatment experience. <b>Patients &amp; methods:</b> Patients answered the Cancer Therapy Satisfaction Questionnaire (CTSQ domains: Satisfaction with Therapy [SWT], Expectations of Therapy [ET], Feelings about Side Effects [FSE]), the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) and the FACT-Bone Pain (FACT-BP) Questionnaire at baseline, during (vists 3 and 5) and after treatment (end of observation; EOO). <b>Results:</b> Data from 72 patients were included. Baseline median CTSQ scores SWT: 66.1 (IQR19.7), ET: 75.0 (IQR45), and FSE 68.8 (IQR 34.4) were unchanged during vists 3 and 5, but the SWT (-3.57 [IQR17.9]) and ET (-5.0 [IQR30]) decreased while FSE was unchanged (0.0 [IQR31.25]) at EOO. The median MAX-PC (18.0 [IQR 49]) score was unchanged (0.0, IQR 6) while the median FACT BP (54.0 [IQR13]) score decreased by -1.0 (IQR 8) at EOO. <b>Conclusion:</b> Japanese metastatic castration resistant prostate cancer patients’ experience is stable during Ra-223 treatment. We wanted to know the treatment experience with Radium-223 (Ra-223) among Japanese prostate cancer patients. Ra-223 is a radioactive molecule used for the treatment of metastatic castration resistant prostate cancer. We asked patients to answer different questionnaires on treatment satisfaction, anxiety and quality of life before, during, and after treatment with Ra-223. Based on the patients’ answers to our questionnaires, treatment satisfaction, anxiety and quality of life remain stable while the patients undergo treatment with Ra-223, but in some aspects may decline after treatment. The results mean that patients’ experience during Ra-223 treatment is stable but patients should share any concerns they have about their treatment with their doctors. A study on Japanese metastatic castration resistant prostate cancer patients who receive Radium-223 therapy showed that treatment satisfaction, anxiety and health-related quality of life remain stable among patients while undergoing Ra-223 treatment.

**研究目的**：本研究旨在探究日本转移性去势抵抗性前列腺癌（metastatic castration-resistant prostate cancer, CRPC）患者接受镭-223（Ra-223）治疗的临床体验。
**患者与方法**：受试者分别在基线期、治疗期间（访视3与访视5）及治疗结束后（观察终点，end of observation, EOO）完成以下问卷：癌症治疗满意度问卷（Cancer Therapy Satisfaction Questionnaire, CTSQ，包含治疗满意度[Satisfaction with Therapy, SWT]、治疗期望[Expectations of Therapy, ET]、不良反应感受[Feelings about Side Effects, FSE]三个维度）、前列腺癌纪念焦虑量表（Memorial Anxiety Scale for Prostate Cancer, MAX-PC）以及FACT骨痛问卷（FACT-Bone Pain Questionnaire, FACT-BP）。
**研究结果**：本研究共纳入72例患者的有效数据。基线期的CTSQ各维度中位数得分分别为：SWT 66.1（四分位距[interquartile range, IQR]19.7）、ET 75.0（IQR 45）、FSE 68.8（IQR 34.4）；在访视3与访视5期间，上述得分均无明显变化。而在观察终点（EOO）时，SWT得分下降3.57（IQR 17.9）、ET得分下降5.0（IQR 30），FSE得分无变化（0.0，IQR 31.25）。前列腺癌纪念焦虑量表（MAX-PC）的中位数得分为18.0（IQR 49），在EOO时未发生改变（0.0，IQR 6）；FACT骨痛问卷（FACT-BP）的中位数得分为54.0（IQR 13），在EOO时下降1.0（IQR 8）。
**研究结论**：日本转移性去势抵抗性前列腺癌患者接受镭-223治疗期间的临床体验保持稳定。本研究针对日本前列腺癌患者接受镭-223治疗的临床体验展开探究，镭-223是一种用于治疗转移性去势抵抗性前列腺癌的放射性药物。受试者在接受镭-223治疗前、治疗期间及治疗后完成了针对治疗满意度、焦虑状态与生存质量的多维度问卷。基于问卷结果，患者在接受镭-223治疗期间，其治疗满意度、焦虑状态与健康相关生存质量均保持稳定，但在治疗结束后部分指标可能出现下降。本研究结果提示，患者在镭-223治疗期间的临床体验较为稳定，但患者应主动与医师沟通治疗相关的任何顾虑。此项针对日本转移性去势抵抗性前列腺癌患者接受镭-223治疗的研究显示，患者在治疗期间的治疗满意度、焦虑状态与健康相关生存质量均保持稳定。